Although biomolecules serve as the primary focus of current scientific development, small molecule drugs have significantly impacted the field of biotechnology and its integration with other disciplines. These drugs are continually updated to enhance accessibility and efficacy for a diverse range of patients.。

Against this backdrop, Lingding Consulting organized the Small Molecule Drug Innovation Leaders Forum 2023 (SMDIL2023) in Shanghai on May 18-19.

Dr. Ke Xu, Co-Founder & CEO of META Pharmaceuticals, along with his research team, was invited to attend the forum. They not only delivered an excellent speech on ‘Small molecule new drug development based on immune-metabolism strategy for various chronic diseases’ but also engaged in academic exchanges with industry pioneers, leaders in new drug development, and scientific frontrunners. It was a highly productive trip.